Table 1 Baseline characteristics of the study cohorts
Variables | CT group(n = 161) | MR group(n = 43) | p value |
|---|---|---|---|
Clinical characteristics | |||
 Gender (%) | |||
  Male | 92(57.14) | 26(60.47) | 0.695 |
  Female | 69(42.86) | 17(39.53) |  |
 Age(> 60 years,%) | |||
  Yes | 85(52.80) | 20(46.51) | 0.464 |
  No | 76(47.20) | 23(53.49) |  |
 History of biliary stones (%) | |||
  Yes | 19(11.80) | 5(11.63) | 0.975 |
  No | 142(88.20) | 38(88.37) |  |
 Hepatitis B virus infection (%) | |||
  Yes | 37(22.98) | 12(27.90) | 0.502 |
  No | 124(77.02) | 31(72.10) |  |
 CA19-9(> 37U/ml,%) | |||
  Yes | 94(58.39) | 22(51.16) | 0.396 |
  No | 67(41.61) | 21(48.84) |  |
 CEA(> 5 ng/ml,%) | |||
  Yes | 59(36.65) | 12(27.90) | 0.285 |
  No | 102(63.35) | 31(72.10) |  |
Pathologic characteristics | |||
 Peripheral tissue invasion (%) | |||
  Yes | 11(6.80) | 1(2.30) | 0.265 |
  No | 150(93.20) | 42(97.70) |  |
 Satellite nodules (%) | |||
  Yes | 31(19.25) | 19(44.19) | 0.001 |
  No | 130(80.75) | 24(55.81) |  |
 Vascular invasion (%) | |||
  Yes | 76(47.19) | 7(16.28) |  < 0.001 |
  No | 85(52.81) | 36(83.72) |  |
 Neural invasion (%) | |||
  Yes | 44(27.33) | 3(7.00) | 0.005 |
  No | 117(72.67) | 40(93.00) |  |
 R0 resection (%) | |||
  Yes | 137(85.09) | 30(69.77) | 0.021 |
  No | 24(14.91) | 13(30.23) |  |
 Lymph node metastasis (%) | |||
  Yes | 45(27.95) | 7(16.28) | 0.119 |
  No | 116(72.05) | 36(83.72) |  |
 Tumor necrosis (%) | |||
  Yes | 29(18.01) | 8(18.60) | 0.929 |
  No | 132(81.99) | 35(81.40) |  |
Imaging features | |||
 Tumor size(> 5 cm,%) | |||
  Yes | 90(55.90) | 19(44.19) | 0.171 |
  No | 71(44.10) | 24(55.81) |  |
 Tumor multiplicity (%) | |||
  Yes | 38(23.60) | 7(16.28) | 0.304 |
  No | 123(76.40) | 36(83.72) |  |
 Tumor boundary (%) | |||
  Infiltrative | 85(52.80) | 13(30.23) | 0.009 |
  Distinct | 76(47.20) | 30(69.77) |  |
 Tumor location (%) | |||
  Peripheral | 127(78.88) | 40(93.00) | 0.033 |
  Perihilar | 34(21.12) | 3(7.00) |  |
 Vascular invasion (%) | |||
  Yes | 55(34.16) | 6(13.95) | 0.009 |
  No | 104(65.84) | 37(86.05) |  |
 Lymph node metastasis (%) | |||
  Yes | 86(53.42) | 7(16.28) |  < 0.001 |
  No | 75(46.58) | 36(83.72) |  |
 Liver cirrhosis (%) | |||
  Yes | 23(14.29) | 4(9.30) | 0.392 |
  No | 138(85.71) | 39(90.70) |  |
 Bile duct invasion (%) | |||
  Yes | 87(54.04) | 10(23.26) |  < 0.001 |
  No | 74(45.96) | 33(76.74) |  |
 Arterial phase enhancement pattern (%) |  |  |  < 0.001 |
  Hyperenhancement | 33(20.49) | 16(37.22) |  |
  Hypoenhancement | 68(42.24) | 12(27.90) |  |
  Rim enhancement | 60(37.27) | 15(34.88) |  |
  HBP SI pattern (%) | NA |  | NA |
  Intermediate |  | 10(23.26) |  |
  Hypointense |  | 33(76.74) |  |
  DWI pattern (%) | NA |  | NA |
  Diffusion restricted area < 1/3 |  | 13(30.23) |  |
  Diffusion restricted area > 1/3 |  | 30(69.77) |  |
 Enhancing capsule (%) |  |  | 0.001 |
  Yes | 55(34.16) | 4(9.30) |  |
  No | 106(65.84) | 39(90.70) |  |